RGC
Regencell Bioscience Holdings Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · HK
$5.79
−2.85%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -73.2%
- Free cash flow
- -29.4%
- Operating cash flow
- -29.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +11.8%
- EBIT
- +20.4%
- Net income
- +16.7%
- EPS
- +17.2%
- Free cash flow
- +18.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025